These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8898930)

  • 41. Antitumor activity of thalidomide in refractory multiple myeloma.
    Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeddis J; Barlogie B
    N Engl J Med; 1999 Nov; 341(21):1565-71. PubMed ID: 10564685
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Therapeutic results and changes in prognosis in patients with multiple myeloma in central and northern Moravia over the past 40 years].
    Scudla V; Bacovský J; Indrák K; Kod'ousková V; Vytrasová M; Faber E; Papajík T; Vavrdová V; Adam Z; Hájek R; Farbiaková V; Srovnalík K; Novosadová L; Vránová M; Micaníková M; Sumná E; Kuca B; Slezar J; Heincová V; Gumulec J; Zivná J; Schlemmer P; Lautnerová E; Lasota Z; Kubecková M; Krajsová I; Růzicka M; Cíhal K; Martínek A; Cernosek B; Doubravský J; Papajík J; Prodĕlal P
    Vnitr Lek; 2002 Aug; 48(8):707-17. PubMed ID: 12425200
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic factors in IgD myeloma: a study of 21 cases.
    Fibbe WE; Jansen J
    Scand J Haematol; 1984 Nov; 33(5):471-5. PubMed ID: 6515330
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
    Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
    Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Browman GP; Bergsagel D; Sicheri D; O'Reilly S; Wilson KS; Rubin S; Belch A; Shustik C; Barr R; Walker I
    J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interferon therapy during the plateau phase of multiple myeloma: an update of a Swedish multicenter study.
    Westin J
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):37-40. PubMed ID: 1948128
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Long-term survival and prognostic factors in stage II-III multiple myeloma treated with conventional chemotherapy].
    Pertuiset E; Chevret S; Lioté F; Delauche MC; Bardin T; Dryll A; Kuntz D
    Ann Med Interne (Paris); 1992; 143(8):519-24. PubMed ID: 1303595
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical response to the treatment of multiple myeloma].
    Sezaki T
    Rinsho Ketsueki; 1989 Aug; 30(8):1216-9. PubMed ID: 2601037
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.
    Jacobs RW; Saliba RM; Sasaki K; Farhan S; Armas A; Shah ND; Bashir Q; Qureshi S; Rondon G; Hosing C; Popat U; Parmar S; Shah JJ; Wang M; Weber DM; Thomas SK; Orlowski RZ; Champlin RE; Qazilbash MH
    Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):36-42. PubMed ID: 26702475
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival.
    Lovell R; Dunn JA; Begum G; Barth NJ; Plant T; Moss PA; Drayson MT; Pratt G;
    Br J Haematol; 2005 Aug; 130(4):542-8. PubMed ID: 16098068
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reappraisal of plateau phase in myeloma.
    Durie BG; Russell DH; Salmon SE
    Lancet; 1980 Jul; 2(8185):65-8. PubMed ID: 6105246
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
    Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
    Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic factors and staging systems of multiple myeloma:
    Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
    Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinical features and status in multiple myeloma].
    Sawamura M; Murakami H; Ogawara H; Tsuchiya J
    Rinsho Ketsueki; 1993 Apr; 34(4):444-9. PubMed ID: 8510331
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic value of clinical, laboratory, and histological characteristics in multiple myeloma: improved definition of risk groups.
    Peest D; Coldewey R; Deicher H; Sailer M; Vykoupil C; Leo R; Georgii A; Karow J; Hoeppner E; Diehl V
    Eur J Cancer; 1993; 29A(7):978-83. PubMed ID: 8499152
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term follow-up of a population based cohort with monoclonal proteinaemia.
    Schaar CG; le Cessie S; Snijder S; Franck PF; Wijermans PW; Ong C; Kluin-Nelemans H
    Br J Haematol; 2009 Jan; 144(2):176-84. PubMed ID: 19036113
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma.
    Lemieux E; Hulin C; Caillot D; Tardy S; Dorvaux V; Michel J; Gastinne T; Rossi C; Legouge C; Touzeau C; Planche L; Loirat M; Lafon I; Moreau P
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):445-9. PubMed ID: 23186983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.